Education
About Us
Working with TipRanks
Follow Us
Replimune Group Inc (REPL)
NASDAQ:REPL
REPL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.68 - $17.00
Previous CloseN/A
Volume95.41K
Average Volume (3M)17.23M
Market Cap
$443.36M
Enterprise Value$523.17M
Total Cash (Recent Filing)$403.34M
Total Debt (Recent Filing)$76.33M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Oct 30, 2025EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding78,055,850
10 Day Avg. Volume3,008,184
30 Day Avg. Volume17,228,841
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue355.42
Enterprise Value/Gross Profit-184.93
Enterprise Value/Ebitda-1.94
Forecast
1Y Price Target
$4.14Price Target Upside-25.14% Downside
Rating ConsensusHold
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Financial StabilityReplimune ended with $403.3M in cash and cash equivalents, guiding to having sufficient cash runway to fund operations into the future.
Pipeline DevelopmentOther pipeline programs remain on track with multiple clinical trials continuing to enroll patients.
Product PotentialTUDRIQEV is likely to be a successful first therapeutic in Replimune's skin cancer franchise, given IGNYTE data in melanoma, which significantly de-risked.
Bears Say
Financial ConcernsReplimune will likely need to re-run its clinical studies to get to approval and may not have enough cash on its books with limited financing options.
Regulatory ChallengesThe FDA issued a Complete Response Letter regarding the Biologics License Application for RP1, which was viewed as a negative surprise.
Trial Design IssuesThe CRL indicated several notable issues with the RP1 program, including the IGNYTE trial not being an adequate well-controlled trial sufficient to demonstrate effectiveness.
Replimune Group News
REPL FAQ
What was Replimune Group Inc’s price range in the past 12 months?
Replimune Group Inc lowest stock price was $2.68 and its highest was $17.00 in the past 12 months.
What is Replimune Group Inc’s market cap?
Replimune Group Inc’s market cap is $443.36M.
When is Replimune Group Inc’s upcoming earnings report date?
Replimune Group Inc’s upcoming earnings report date is Oct 30, 2025 which is in 63 days.
How were Replimune Group Inc’s earnings last quarter?
Replimune Group Inc released its earnings results on Aug 07, 2025. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.794 by -$0.156.
Is Replimune Group Inc overvalued?
According to Wall Street analysts Replimune Group Inc’s price is currently Overvalued.
Does Replimune Group Inc pay dividends?
Replimune Group Inc does not currently pay dividends.
What is Replimune Group Inc’s EPS estimate?
Replimune Group Inc’s EPS estimate is -0.77.
How many shares outstanding does Replimune Group Inc have?
Replimune Group Inc has 78,055,850 shares outstanding.
What happened to Replimune Group Inc’s price movement after its last earnings report?
Replimune Group Inc reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.794. Following the earnings report the stock price went down -0.364%.
Which hedge fund is a major shareholder of Replimune Group Inc?
Currently, no hedge funds are holding shares in REPL
Replimune Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.14 (-25.14% Downside)
$4.14 (-25.14% Downside)
Blogger Sentiment
Bullish
REPL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 37.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $49.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.80%
12-Months-Change
Fundamentals
Return on Equity
-73.44%
Trailing 12-Months
Asset Growth
-12.24%
Trailing 12-Months
Company Description
Replimune Group Inc
Replimune Group, Inc. (REPL) is a biotechnology company focused on developing oncolytic immunotherapies for the treatment of cancer. The company operates in the healthcare sector, specifically within the biopharmaceutical industry. Replimune's core products are based on its proprietary Immulytic platform, which is designed to enhance the systemic anti-tumor immune response by using genetically engineered viruses to selectively infect and kill cancer cells while sparing normal tissue.
REPL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call provided a positive outlook, highlighting significant regulatory achievements, strong commercial readiness, and financial stability. However, the increase in net loss and operational expenses presents challenges. The overall sentiment is optimistic about RP1's potential launch and market adoption.View all REPL earnings summariesREPL Stock 12 Month Forecast
Average Price Target
$4.14
▼(-25.14% Downside)
Technical Analysis
Anavex Life Sciences
―
Arcus Biosciences
―
Oric Pharmaceuticals
―
Nurix Therapeutics
―
Sana Biotechnology
―
Ownership Overview
Currently, No data available
---